Tilray Brands (NASDAQ:TLRY) Upgraded to “Hold” at Wall Street Zen

Tilray Brands (NASDAQ:TLRY) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

A number of other brokerages also recently weighed in on TLRY. Roth Mkm decreased their price objective on shares of Tilray Brands from $20.00 to $10.00 and set a “neutral” rating for the company in a research report on Tuesday, January 20th. Canaccord Genuity Group began coverage on Tilray Brands in a research report on Tuesday, January 27th. They set a “hold” rating on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Tilray Brands in a research note on Wednesday, January 21st. Zacks Research raised Tilray Brands from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 11th. Finally, ATB Cormark Capital Markets raised Tilray Brands from a “strong sell” rating to a “hold” rating in a report on Wednesday, December 10th. One research analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Tilray Brands currently has an average rating of “Hold” and an average target price of $13.33.

Tilray Brands Price Performance

NASDAQ:TLRY opened at $6.21 on Friday. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.81 and a quick ratio of 1.72. The firm has a market cap of $723.53 million, a price-to-earnings ratio of -0.28 and a beta of 1.96. The company has a 50 day moving average price of $7.83 and a 200-day moving average price of $10.54. Tilray Brands has a 1-year low of $3.51 and a 1-year high of $23.20.

Tilray Brands (NASDAQ:TLRY) last announced its quarterly earnings results on Thursday, January 8th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.12. The firm had revenue of $217.51 million for the quarter, compared to the consensus estimate of $211.15 million. Tilray Brands had a negative net margin of 251.69% and a negative return on equity of 6.35%. During the same period in the prior year, the firm posted ($0.03) earnings per share. Equities research analysts forecast that Tilray Brands will post -0.2 EPS for the current year.

Institutional Trading of Tilray Brands

Institutional investors and hedge funds have recently modified their holdings of the stock. Hilton Head Capital Partners LLC acquired a new position in shares of Tilray Brands during the 4th quarter worth about $38,000. Engineers Gate Manager LP purchased a new stake in Tilray Brands during the 4th quarter worth approximately $126,000. Oppenheimer & Co. Inc. acquired a new position in shares of Tilray Brands during the third quarter valued at approximately $25,000. Silverlake Wealth Management LLC acquired a new position in Tilray Brands in the 3rd quarter valued at $25,000. Finally, Unified Investment Management acquired a new stake in shares of Tilray Brands in the third quarter valued at about $26,000. Hedge funds and other institutional investors own 9.35% of the company’s stock.

Tilray Brands News Roundup

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Tilray Medical announced its largest medical-cannabis portfolio expansion in Australia, reinforcing patient access and signaling commitment to a growth market — a revenue and patient-share catalyst for TLRY’s medical segment. Tilray Medical Announces Major Expansion of Medical Cannabis Portfolio in Australia
• Positive Sentiment: Tilray Medical, CC Pharma and 14U Pharma formed a strategic alliance with “gesund leben” and Alliance Healthcare Deutschland to accelerate market expansion in Germany — a distribution and commercialization boost for EU sales. Tilray Medical, CC Pharma, and 14U Pharma Announce Strategic Alliance
• Positive Sentiment: CEO Irwin Simon told Just Drinks the company is focused on “putting stability in place” for BrewDog — signaling management attention on operational turnaround and margin stabilization in its beverage segment. “We need to put stability in place” – Tilray Brands CEO on what lies ahead for BrewDog
• Neutral Sentiment: Market write-ups note TLRY is slipping more than the broader market in recent sessions—useful short-term context but largely descriptive of current flow rather than new fundamental news. Tilray Brands, Inc. (TLRY) Dips More Than Broader Market: What You Should Know
• Negative Sentiment: Technical analysts warn TLRY has lost a key support level and suggest downside toward ~$5 is possible if selling continues — a short-term bearish signal that can amplify downside as stops trigger. Tilray stock price has just lost a key support: is a crash to $5 coming?

Tilray Brands Company Profile

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.